Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
None of my beeswax but do you have a small investment in HSCS?
Those are two great questions Cloudera. I immediately did a very quick search for Omacor in England and clicked on the very first result. Oxford Pharmacy selling Omacor, 1000 mg caps - 28 for 25 pounds:
https://www.oxfordonlinepharmacy.co.uk/high-cholesterol/omacor-omega-3-acid-1000mg-28-capsules#
Now, of course some of those taking Omacor will only take two caps a day, maybe some only one a day, but if they take 4 caps a day then you are looking at 100 pounds for a month's supply. Don't remember the cost of Vazkepa to the end user there after reimbursement.
Interesting it was just described as under accumulation the other day, and now inder distribution. Must have been just barely under accumulation for it to swing the other way that quickly
Thanks Capt for that info about Omacor in the UK. Glad they have followed the EU on that.
Well, let me throw this out, as I know jack about this type of process. Were they marketing the company with a BO price in mind?
For example if you put your house on the market for 5 million bucks but it is only worth $500K will you get any offers?
So, anyone familiar with this strategic review can opine as to whether there was a top line number shopped around. If no number whatsoever
was shopped, and they still got no offers (which they didn't) then all are screwed.
If, however, there was an asking price that was grossly overpriced, then there still might be an opportunity at a more realistic valuation.
So do you think Armistice knew about this strategic review fail when the added over 3 millions shares a couple of days ago?
Thanks. It seemed like it was taking way too long with no news.
Thanks for posting. Reason for late rise in sp today? Maybe more fireworks tomorrow.
Thanks Capt. Of course KM and Amarin are no different than most companies. But back in the 50's the wage ratio between CEO and common worker was much different.
https://en.wikipedia.org/wiki/Wage_ratio#:~:text=By%20comparison%2C%20it%20is%20estimated,been%20observed%20around%20the%20world.
What is most galling is that some of these CEOs make ungodly sums of money while destroying their companies - not boosting or making them thrive.
Thanks for the clarification Capt
I can't quickly pull up a chart of the script levels but I believe there was a pretty good uptick from the time of label expansion approval (Dec) up until the end of March (DuDisaster). Of course the Super Bowl would have been halfway through that period, so hard to tell how much it impacted scripts. However, right now, much of the scripts for V going to Generic so it would not seem to be a great value at this time.
Like Caddiedad said, the old guard spent that just to try to keep their cushy jobs.
Or someone not rotating stock properly.
Thanks North. Is it the court that sets arguments and hence could it be the court moving slowly or is the onus strictly on the parties? I know you indicated some of the possibilities (settlement being one) but is it normal for arguments not to be scheduled by that time frame?
Bet a little on this move up. Not sure if it is a little early as we won’t get much news before 2Q. Hope it is not a pump just for them to raise cash. They will need to raise but when?
North, I am not sure. That was all I could find.
Not fond of the word "expected", as when expectations are not exceeded, there is a sell the news event. However, you are correct that as the trajectory improves with profits increasing consistently over time, the share price will take care of itself.
Kiwi, I was indicating that BP often bought companies either prior to or shortly after P3 trial results. I will keep an eye on it. If the goal line is that far away, the stock price will come back down to a better entry point. Have a great weekend. If we can get a little bit more traction in the EU, our stock price here with Amarin may be able to sustain a steady rise.
Thanks Kiwi but a couple of weeks too late.
As crazy as it sounds it sometimes easier to get people to believe nefarious fables than the truth.
Of course that is the case we should see a sharp rise in scripts right?
A couple decades ago I was in Elan and watched it rise from the ashes twice, so I am hoping to experience the same thing here. A of us on this board have been here for more than a decade or decade and a half. Most would like to montize this and move on. Hopefully, as we are starting to see the signs, this new management does the trick.
As a man of science and not superstition, I shouldn’t say the following but:
I’ve stopped buying because the chances are high that a stock drops after I buy it. I want Amarin stock to continue to rise so I won’t do anything to stop that momentum. Of course I also have more than enough shares already so this definitely not advice to anyone who wants or needs to buy more.
Best of luck to you and all the rest of us.
Bouf, or anyone else, do you have an opinion why the Glaxo -Teva decision by the SC to let the decision stand, has not caused the Generics, Insurance Cos, et al, to stop infringing on the R-I indication? TIA.
Seems there are a number of studies that confirm or at least show that higher cholesterol after a certain age actually is associated with longer lifespan.
You are correct about his contributions here in the past and no question we all would be better off if he were in the fold.
He is a pharmacist in Ontario and we all know his real name. He has been a strong advocate for Vascepa and has tried to educate
as many as he could. Unfortunately (not for us or Amarin imo but rather to create a situation with PD and others) the proxy situation caused
people to take sides and unfortunately (again) PD didn't quickly and easily accept the result and showed some bitterness. Hopefully time cures all and we can benefit again from his knowledge and insight.
Saw this on another board and realize it is a bit dated (plus the fact that things move at a snail’s pace in Congress) but maybe some hope for those onerous PAs:
https://www.ama-assn.org/practice-management/prior-authorization/big-step-forward-congress-fix-prior-authorization
Not sure if this has already been discussed here, if so apologies for posting.
Jasbg, Zip, do we know whether this has been attempted before by any Pharma trying to get Generics off the market by supplying some data to the FDA, and if so have these attempts been successful?
I ask because the FDA has their protocols for approving generics and I could see their resistance to this as it also calls into questions their procedures.
On the other hand, there are numerous instances where the FDA has removed products off the market because of their danger or side effects.
So just thinking about this, Sabouret is the President of the National College of Cardiology in France. Does he not have any influence in terms of getting the French government to shake a leg and set up reimbursement for V?
Kiwi you have peaked my interest in EWTX
The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.
It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.
Is this reiteration to keep the stock price up over a buck in lieu of buying more shares?
Thanks for posting. Isn’t this just a rehash of what they said 10 or so days ago?
I am also hoping that the MarketEdge piece that ORBAPU posted plays out. Buying stopped after we went touched 1.30 and profit taking ensued for a number of days after. It is now oversold, the momo guys have taken their profits, and this is ready to climb all by itself (well not by itself but without necessarily the need for Denner's gang to get involved). So hoping that by Tuesday night we are well above the 1 buck mark.
Thanks for posting. I think we should stick Nissen's nose in this:
"First of all, we did a responder analysis of the trial patients in the placebo arm looking at those who increased CRP or LDL cholesterol or both compared to those who did not, and it's very striking that their events are the same. That does not seem to account for direct harm in the placebo patients from mineral oil."
AND have him issue a retraction of his prior statements and an apology.
Your post makes me wonder about RWE for V wrt CVD. Surely the insurers must have that. Or is there anything in HIPPA that precludes looking at that?
Ah, that makes sense. I guess too early for my brain to click in.
Gouging. And, I doubt the Generic companies are now charging Cigna 10 times more for the drug.
JRoon, I am wondering if anyone has any idea what the split is between cardios prescribing V versus primary care physicians prescribing V?
I saw this quote from Dr. Bhatt back in 2019 where he thought that specialized docs would start prescribing but that eventually we would see primary care physicians writing. I got mine from my primary care doc.
""Now, the key challenge is to identify and treat appropriate patients," Bhatt noted. He says this task will largely fall on cardiologists, endocrinologists, and primary care physicians, though stroke neurologists, nephrologists, and vascular medicine specialists will also have patients for whom the data are relevant.
"I believe the drug will ultimately be widely prescribed, initially by subspecialists, but by primary care physicians also. It is overall very well tolerated, safe, and easy to use," he said. "Much like statin prescription started in subspecialty practices but then became quite common in primary care, I envision the same happening with icosapent ethyl."
https://www.medscape.com/viewarticle/922865?form=fpf
Wow, that's highway robbery for the GV. They are making a killing - assuming they have a good amount of insured taking the stuff.
Also, are you sure about the 90? All the V and GV I have seen come in bottles of 120.